Vertex Therapeutics (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN) have swum against the tide all year, with their shares rising as the S&P 500 has struggled. The biotech companies have strong fundamentals in their favor, but both could do even better in 2023.

 While Vertex's pipeline is about to extend well beyond cystic fibrosis (CF), Amgen's combination of emerging drugs, plus the accretive nature of its deal to buy Horizon Therapeutics, could reward investors in the long run.

Let's take a deeper look at these businesses and see why they are solid investments for the near future. 

Continue reading

Source Fool.com